Alert J.
62
Coauthors
4
Documentos
Volumen de publicaciones por año
Cargando gráfico
| Año de publicación | Num. Publicaciones |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
Publicaciones por áreas de conocimiento
Cargando gráfico
| Área de conocimiento | Num. Publicaciones |
|---|---|
| Cáncer | 4 |
| Medicina interna | 2 |
| Medicamento | 1 |
Publicaciones por áreas temáticas
Cargando gráfico
| Área temática | Num. Publicaciones |
|---|---|
| Enfermedades | 4 |
| Farmacología y terapéutica | 3 |
| Cirugía y especialidades médicas afines | 1 |
| Medicina y salud | 1 |
Principales fuentes de datos
| Origen | Num. Publicaciones |
|---|---|
| Scopus | 4 |
| Google Scholar | 0 |
| RRAAE | 0 |
Cargando gráfico
Coautores destacados por número de publicaciones
| Coautor | Num. Publicaciones |
|---|---|
| Tania Crombet | 4 |
| Luaces P.L.o. | 4 |
| Marinello J.J.u. | 2 |
| Solomón M.T.e. | 2 |
| Martell J.A.n. | 2 |
| Chon I. | 1 |
| Jorrín E. | 1 |
| Miranda N. | 1 |
| Rivero T.C. | 1 |
| Pérez K. | 1 |
Cargando gráfico
Top Keywords
Cargando gráfico
Publicaciones del autor
Nimotuzumab in combination with radiotherapy in high grade glioma patients: A single institution experience
ArticleAbstract: Nimotuzumab, a humanized antibody targeting epidermal growth factor receptor, has potent anti-prolifPalabras claves:Anaplastic astrocytoma, glioblastoma multiforme, High grade glioma, Monoclonal antibody, nimotuzumab, RadiotherapyAutores:Alert J., Chon I., Jorrín E., Luaces P.L.o., Marinello J.J.u., Miranda N., Solomón M.T.e., Tania CrombetFuentes:scopusTreatment of malignant, non-resectable, epithelial origin esophageal tumors with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy
ArticleAbstract: Overexpression of epidermal growth factor receptor in esophageal cancer is associated with poor progPalabras claves:Chemorariotherapy, Esophageal cancer, Humanized monoclonal, nimotuzumabAutores:Albuerne Y.A., Alert J., Alvarez E.S., Callejo I.P., De La Vega H.A., Gonzalez C.E.V., Gonzalez Y.S., Hernadez I.M., Lazo N.G., Luaces P.L.o., Martell J.A.n., Moreno B.P., Perez M.L., Ramos-Suzarte M., Ruiz-Garcia E.B., Soriano J.L., Tania CrombetFuentes:scopusRadiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial
ArticleAbstract: BACKGROUND: The prognosis of patients bearing high grade glioma remains dismal. Epidermal Growth FacPalabras claves:Autores:Alert J., Bach F., Ballesteros J., Catala M., de-Castro N., Domíngez R., Figueredo J., Griego M.G.o., Luaces P.L.o., Marinello J.J.u., Martell J.A.n., Quintanal N., Salva S., Selva J.C.é., Solomón M.T.e., Tania Crombet, Toledo C., Vaquer J.Fuentes:scopusNimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck
ArticleAbstract: The prognosis of patients with advanced head and neck cancer remain dismal. For this tumor type, elePalabras claves:Epidermal growth factor receptor, immunotherapy, Monoclonal antibody, nimotuzumab, Squamous cell carcinoma of the head and neck, Targeted therapyAutores:Alert J., Bahi R.D.C., Bárbara Wilkinson, Bilbao M.A., Carmen Elena Viada, De Armas E.L., Frómeta M., Galainena J.J., Gracias E., Iznaga N., Leonard I., Luaces P.L.o., Muchuli C.R., Mulén B., Mullens V., Pérez K., Pineda I., Rivero T.C., Rodríguez E., Rodríguez M.O., Tania Crombet, Torres O., Vinageras E.N.Fuentes:scopus